Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

PHASE-SPECIFIC EVALUATION OF COST-EFFECTIVENESS FOR LUNG TRANSPLANT AND EX-VIVO LUNG PERFUSION

EF 2018-19

Résumé
Patients with lung disease not responsive to medical therapy may undergo lung transplant as a definitive surgical therapy. Lung transplants have been shown to improve quality of life for patients with severe lung disease, and has been shown to extend length of life. However, the frequency with which donor lungs are determined to be of inadequate quality for transplant and the increasing enlistment of patients on the transplant wait-list means that the demand for lung transplant exceeds the available organ supply. Close to 20% of patients die while waiting for donor lungs. Ex-vivo lung perfusion (EVLP) is a promising new technology which allows for rehabilitation of donor lungs prior to transplant in a recipient. This technology has been shown to be safe and effective. However, the effect that EVLP may have on rates of lung transplant are yet to be determined. Lung transplant and EVLP may offer improved survival and quality of life for patients with severe lung disease, but these technologies come at significant cost to the healthcare system. Few studies have investigated the cost-effectiveness of lung transplant programs, and none has done so in the Canadian context. It remains unclear how cost-effective lung transplant programs are, and what impact, if any, EVLP may have on program efficiency. Further implementation of EVLP in transplant programs must be supported by data that reflects a value-added to patients as well as to the healthcare system. We propose to use health technology assessment principles to study cost-effectiveness of lung transplant and EVLP at one of the world’s largest lung transplant centers. This project aims to demonstrate that EVLP may increase the number of potential organs for transplant and improve patient outcomes following transplant.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
406357
Name
Peel John K
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
PHASE-SPECIFIC EVALUATION OF COST-EFFECTIVENESS FOR LUNG TRANSPLANT AND EX-VIVO LUNG PERFUSION
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cost-Effectiveness Study; Epidemiology; Ex-Vivo Lung Perfusion; Health Technology Assessment; Lung Transplant
Abstract
Patients with lung disease not responsive to medical therapy may undergo lung transplant as a definitive surgical therapy. Lung transplants have been shown to improve quality of life for patients with severe lung disease, and has been shown to extend length of life. However, the frequency with which donor lungs are determined to be of inadequate quality for transplant and the increasing enlistment of patients on the transplant wait-list means that the demand for lung transplant exceeds the available organ supply. Close to 20% of patients die while waiting for donor lungs. Ex-vivo lung perfusion (EVLP) is a promising new technology which allows for rehabilitation of donor lungs prior to transplant in a recipient. This technology has been shown to be safe and effective. However, the effect that EVLP may have on rates of lung transplant are yet to be determined. Lung transplant and EVLP may offer improved survival and quality of life for patients with severe lung disease, but these technologies come at significant cost to the healthcare system. Few studies have investigated the cost-effectiveness of lung transplant programs, and none has done so in the Canadian context. It remains unclear how cost-effective lung transplant programs are, and what impact, if any, EVLP may have on program efficiency. Further implementation of EVLP in transplant programs must be supported by data that reflects a value-added to patients as well as to the healthcare system. We propose to use health technology assessment principles to study cost-effectiveness of lung transplant and EVLP at one of the world’s largest lung transplant centers. This project aims to demonstrate that EVLP may increase the number of potential organs for transplant and improve patient outcomes following transplant.
Competitiondate
201812
Approvedterm2
1 yr 0 mth
Pinamesdelim
Peel, John K
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~